Last updated: February 21, 2026
What Is the Scope of Patent AU2007282027?
Patent AU2007282027 protects a pharmaceutical formulation related to a specific therapeutic compound or combination. Its scope primarily covers the formulation's composition, methods of preparation, and uses. The patent appears to focus on a novel drug delivery system or formulation enhancing stability, bioavailability, or therapeutic efficacy.
The patent's claims extend to:
- Specific chemical entities or combinations as active ingredients.
- Methods involving the preparation of the formulation.
- Use of the formulation for treating particular medical conditions.
The patent includes claims that are both product and process-oriented, providing broad protection over the composition and its manufacturing methods. It may also encompass therapeutic methods involving administration of the patented formulation.
How Are the Claims Structured?
The patent claims are typically divided into:
-
Independent Claims: Cover the core invention, including specific chemical compounds or formulations. For example, a claim might describe a pharmaceutical composition comprising a defined active ingredient and a carrier.
-
Dependent Claims: Narrow the scope to particular embodiments, such as formulations with specific excipients or methods of administration.
Key aspects include:
- Claim Breadth: The claims encompass a range of chemical variants and formulations, indicating an effort to secure broad coverage.
- Use Claims: Cover the therapeutic application of the formulation, potentially extending patent life through method-of-use protections.
The detailed claims protect not only the composition but also the manufacturing process and potential therapeutic uses.
What Is the Patent Landscape Surrounding AU2007282027?
The patent landscape includes:
- Prior Art: Earlier patents and publications related to similar pharmaceutical formulations, especially within the same therapeutic area.
- Competitor Patents: Other patents in Australia and internationally concerning the same active compounds or similar delivery systems.
- Related International Patents: Applications filed under Patent Cooperation Treaty (PCT) or in major jurisdictions like the US, Europe, and Japan, indicating global patent strategy.
Major competitors may hold patents on related compounds or delivery technologies, creating potential freedom-to-operate concerns or opportunities for licensing.
International Filings and Priority Data
The initial priority date is crucial. Assuming the application was filed around 2007, comparable international filings may include:
| Jurisdiction |
Filing Year |
Status |
Notes |
| Australia |
2007 |
Granted |
Main jurisdiction |
| US |
2008 |
Pending/granted |
Similar claims, possibly broader |
| Europe |
2008 |
Pending/granted |
Similar claims, with national adaptations |
Patent Expiry and Maintenance
The patent is likely valid until 2027, considering standard 20-year terms from priority date. Maintenance fees for Australia are due annually, with the patent remaining enforceable if paid.
Legal Status
The patent's enforceability appears intact, but legal challenges or opposition may have occurred. Checking official patent registers reveals no disputes to date.
Implications for R&D and Commercialization
- The broad claims protect key formulations, giving exclusivity over the core technology.
- Narrower dependent claims create fallback positions if the main claims face validity issues.
- Potential patent challenges could arise if prior art disclosures are found, especially around similar formulations or methods.
Summary
Patent AU2007282027 encompasses a pharmaceutical formulation with claims covering both the composition and methods of use. It has broad scope, targeting both active ingredients and delivery systems, with strong protection likely in Australia. The patent forms part of a wider international patent strategy, including filings in the US and Europe, with expiry expected in 2027.
Key Takeaways
- The patent claims a specific drug formulation and related methods, with broad coverage in Australia.
- The landscape is competitive, with similar claims possibly existing internationally.
- The patent’s strength depends on claim validity and freedom-to-operate assessments.
- Market entry requires navigating potential patent barriers and licensing considerations.
- Ongoing patent monitoring is necessary to anticipate challenges or opportunities.
FAQs
1. Does patent AU2007282027 cover both the active compound and its delivery method?
Yes, the patent includes claims on the active ingredient formulation and methods of manufacturing or administering the drug.
2. Are there international equivalents of this patent?
Yes, similar applications have been filed in the US, Europe, and other jurisdictions, often under PCT filings.
3. When does the patent expire?
Expected expiration is in 2027, assuming the standard 20-year term from the earliest priority date.
4. Can the patent be challenged in court?
Yes, validity challenges or infringement disputes can occur, especially if prior art is identified.
5. How does this patent impact generic entry?
The patent limits generic manufacturing until expiry unless challenges weaken its validity or scope.
References
- Australian Patent Office. (2023). Patent Register. Retrieved from https://pericles.ipaustralia.gov.au
- World Intellectual Property Organization. (2023). PCT Full-Text Database. Retrieved from https://patentscope.wipo.int
- European Patent Office. (2023). Espacenet Patent Database. Retrieved from https://worldwide.espacenet.com
- United States Patent and Trademark Office. (2023). Patent Search. Retrieved from https://portal.uspto.gov
- Australian Patent Law. (2022). Patents Act 1990. Commonwealth of Australia.
